USRE37650E1
(en)
|
1991-05-10 |
2002-04-09 |
Aventis Pharmacetical Products, Inc. |
Aryl and heteroaryl quinazoline compounds which inhibit CSF-1R receptor tyrosine kinase
|
US5710158A
(en)
*
|
1991-05-10 |
1998-01-20 |
Rhone-Poulenc Rorer Pharmaceuticals Inc. |
Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
|
US5721237A
(en)
*
|
1991-05-10 |
1998-02-24 |
Rhone-Poulenc Rorer Pharmaceuticals Inc. |
Protein tyrosine kinase aryl and heteroaryl quinazoline compounds having selective inhibition of HER-2 autophosphorylation properties
|
US5480883A
(en)
*
|
1991-05-10 |
1996-01-02 |
Rhone-Poulenc Rorer Pharmaceuticals Inc. |
Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
|
CA2102780C
(en)
*
|
1991-05-10 |
2007-01-09 |
Alfred P. Spada |
Bis mono-and bicyclic aryl and heteroaryl compounds which inhibit egf and/or pdgf receptor tyrosine kinase
|
US6645969B1
(en)
|
1991-05-10 |
2003-11-11 |
Aventis Pharmaceuticals Inc. |
Aryl and heteroaryl quinazoline compounds which inhibit CSF-1R receptor tyrosine kinase
|
US5714493A
(en)
*
|
1991-05-10 |
1998-02-03 |
Rhone-Poulenc Rorer Pharmaceuticals, Inc. |
Aryl and heteroaryl quinazoline compounds which inhibit CSF-1R receptor tyrosine kinase
|
GB9121943D0
(en)
*
|
1991-10-16 |
1991-11-27 |
Sandoz Ltd |
Organic compounds,processes for their production and their use
|
GB9300059D0
(en)
*
|
1992-01-20 |
1993-03-03 |
Zeneca Ltd |
Quinazoline derivatives
|
US5712395A
(en)
*
|
1992-11-13 |
1998-01-27 |
Yissum Research Development Corp. |
Compounds for the treatment of disorders related to vasculogenesis and/or angiogenesis
|
US5981569A
(en)
*
|
1992-11-13 |
1999-11-09 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem |
Substituted phenylacrylonitrile compounds and compositions thereof for the treatment of disease
|
US5792771A
(en)
*
|
1992-11-13 |
1998-08-11 |
Sugen, Inc. |
Quinazoline compounds and compositions thereof for the treatment of disease
|
US5763441A
(en)
*
|
1992-11-13 |
1998-06-09 |
Sugen, Inc. |
Compounds for the treatment of disorders related to vasculogenesis and/or angiogenesis
|
GB9323290D0
(en)
|
1992-12-10 |
1994-01-05 |
Zeneca Ltd |
Quinazoline derivatives
|
US5409886A
(en)
*
|
1993-02-18 |
1995-04-25 |
Mitsui Toatsu Chemicals, Incorporated |
3-pyrroline-2-one derivatives and herbicidal compositions containing same
|
US5451603A
(en)
*
|
1993-03-11 |
1995-09-19 |
Zymogenetics, Inc. |
3,4-diarylchromans for treatment of dermatitis
|
GB9314893D0
(en)
*
|
1993-07-19 |
1993-09-01 |
Zeneca Ltd |
Quinazoline derivatives
|
GB9325217D0
(en)
*
|
1993-12-09 |
1994-02-09 |
Zeneca Ltd |
Pyrimidine derivatives
|
US5416098A
(en)
*
|
1993-12-30 |
1995-05-16 |
Zymogenetics, Inc. |
Method for treating dermatitis and related conditions
|
US5700823A
(en)
*
|
1994-01-07 |
1997-12-23 |
Sugen, Inc. |
Treatment of platelet derived growth factor related disorders such as cancers
|
IL112249A
(en)
|
1994-01-25 |
2001-11-25 |
Warner Lambert Co |
Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds
|
IL112248A0
(en)
*
|
1994-01-25 |
1995-03-30 |
Warner Lambert Co |
Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them
|
BR9506936A
(pt)
*
|
1994-02-23 |
1997-09-09 |
Pfizer |
Derivados de quinazolina substituídos com 4-heterociclila processos para sua preparaçao e seu uso como agentes anticancerosos
|
AU2096895A
(en)
*
|
1994-03-07 |
1995-09-25 |
Sugen, Incorporated |
Receptor tyrosine kinase inhibitors for inhibiting cell proliferative disorders and compositions thereof
|
US5578609A
(en)
*
|
1994-03-25 |
1996-11-26 |
The Dupont Merck Pharmaceutical Company |
2-carbocyclic and 2-heterocyclic quinoline-4-carboxylic acids and salts thereof useful as immunosuppressive agents
|
US5523408A
(en)
*
|
1994-03-25 |
1996-06-04 |
The Dupont Merck Pharmaceutical Company |
2-carbocyclic and 2-heterocyclic quinoline-4-carboxylic acids and salts thereof useful as immunosuppressive agents
|
DE59500788D1
(de)
*
|
1994-05-03 |
1997-11-20 |
Ciba Geigy Ag |
Pyrrolopyrimidinderivate mit antiproliferativer Wirkung
|
GB9514160D0
(en)
*
|
1994-07-25 |
1995-09-13 |
Zeneca Ltd |
Aromatic compounds
|
GB9417532D0
(en)
*
|
1994-08-31 |
1994-10-19 |
Zeneca Ltd |
Aromatic compounds
|
US5476851A
(en)
*
|
1994-09-08 |
1995-12-19 |
Rhone-Poulenc Rorer Pharmaceuticals, Inc. |
Pyrazolo[3,4-g]quinoxaline compounds which inhibit PDGF receptor protein tyrosine kinase
|
US5804396A
(en)
*
|
1994-10-12 |
1998-09-08 |
Sugen, Inc. |
Assay for agents active in proliferative disorders
|
GB9420557D0
(en)
*
|
1994-10-12 |
1994-11-30 |
Zeneca Ltd |
Aromatic compounds
|
ES2219670T3
(es)
*
|
1994-11-10 |
2004-12-01 |
Millennium Pharmaceuticals, Inc. |
Utilizacion de compuestos de pirazola para el tratamiento de la glomerulonefritis, cancer, ateroesclerosis o restenosis.
|
TW321649B
(es)
*
|
1994-11-12 |
1997-12-01 |
Zeneca Ltd |
|
IL115256A0
(en)
*
|
1994-11-14 |
1995-12-31 |
Warner Lambert Co |
6-Aryl pyrido (2,3-d) pyrimidines and naphthyridines and their use
|
GB9424233D0
(en)
*
|
1994-11-30 |
1995-01-18 |
Zeneca Ltd |
Quinazoline derivatives
|
US6562854B2
(en)
|
1994-12-14 |
2003-05-13 |
Axys Pharmaceuticals, Inc. |
Compositions comprising a substituted benzimidazole useful for treating immunomediated inflammatory disorders
|
RU2164224C2
(ru)
*
|
1995-03-14 |
2001-03-20 |
Новартис Аг |
Трехзамещенные фенильные производные и фармацевтическая композиция
|
EP2163546B1
(en)
|
1995-03-30 |
2016-06-01 |
Pfizer Products Inc. |
Quinazoline derivatives
|
ES2150113T3
(es)
*
|
1995-04-03 |
2000-11-16 |
Novartis Ag |
Derivados de pirazol y procedimientos para la preparacion de los mismos.
|
US5721277A
(en)
*
|
1995-04-21 |
1998-02-24 |
Sugen, Inc. |
Compounds and methods for inhibiting hyper-proliferative cell growth
|
GB9508537D0
(en)
*
|
1995-04-27 |
1995-06-14 |
Zeneca Ltd |
Quinazoline derivatives
|
GB9508538D0
(en)
*
|
1995-04-27 |
1995-06-14 |
Zeneca Ltd |
Quinazoline derivatives
|
GB9508535D0
(en)
*
|
1995-04-27 |
1995-06-14 |
Zeneca Ltd |
Quinazoline derivative
|
GB9508565D0
(en)
*
|
1995-04-27 |
1995-06-14 |
Zeneca Ltd |
Quiazoline derivative
|
EP0824525B1
(en)
*
|
1995-04-27 |
2001-06-13 |
AstraZeneca AB |
Quinazoline derivatives
|
IL117923A
(en)
*
|
1995-05-03 |
2000-06-01 |
Warner Lambert Co |
Anti-cancer pharmaceutical compositions containing polysubstituted pyrido¬2,3-d¾pyrimidine derivatives and certain such novel compounds
|
US5620981A
(en)
*
|
1995-05-03 |
1997-04-15 |
Warner-Lambert Company |
Pyrido [2,3-D]pyrimidines for inhibiting protein tyrosine kinase mediated cellular proliferation
|
US6331555B1
(en)
|
1995-06-01 |
2001-12-18 |
University Of California |
Treatment of platelet derived growth factor related disorders such as cancers
|
US5747498A
(en)
|
1996-05-28 |
1998-05-05 |
Pfizer Inc. |
Alkynyl and azido-substituted 4-anilinoquinazolines
|
US5710173A
(en)
*
|
1995-06-07 |
1998-01-20 |
Sugen, Inc. |
Thienyl compounds for inhibition of cell proliferative disorders
|
US5880141A
(en)
*
|
1995-06-07 |
1999-03-09 |
Sugen, Inc. |
Benzylidene-Z-indoline compounds for the treatment of disease
|
CA2222545A1
(en)
*
|
1995-06-07 |
1996-12-19 |
Sugen, Inc. |
Quinazolines and pharmaceutical compositions
|
WO1996040629A1
(en)
*
|
1995-06-07 |
1996-12-19 |
Sugen, Inc. |
Tyrphostin-like compounds for the treatment of cell proliferative disorders or cell differentiation disorders
|
US5650415A
(en)
*
|
1995-06-07 |
1997-07-22 |
Sugen, Inc. |
Quinoline compounds
|
US5763470A
(en)
*
|
1995-06-07 |
1998-06-09 |
Sugen Inc. |
Benzopyran compounds and methods for their use
|
US6316635B1
(en)
|
1995-06-07 |
2001-11-13 |
Sugen, Inc. |
2-indolinone derivatives as modulators of protein kinase activity
|
US6147106A
(en)
|
1997-08-20 |
2000-11-14 |
Sugen, Inc. |
Indolinone combinatorial libraries and related products and methods for the treatment of disease
|
US5773459A
(en)
*
|
1995-06-07 |
1998-06-30 |
Sugen, Inc. |
Urea- and thiourea-type compounds
|
TW434240B
(en)
|
1995-06-20 |
2001-05-16 |
Zeneca Ltd |
Aromatic compounds, preparation thereof and pharmaceutical composition comprising same
|
TW502026B
(en)
|
1995-06-20 |
2002-09-11 |
Zeneca Ltd |
Aromatic compounds useful as antagonists of e-type prostaglandins, processes for the preparation thereof, pharmaceutical compositions comprising the compounds, and intermediates
|
BR9609617B1
(pt)
*
|
1995-07-06 |
2010-07-27 |
|
derivados de 7h-pirrol[2,3-d]pirimidina, e composição farmacêutica.
|
US5834468A
(en)
|
1995-07-07 |
1998-11-10 |
Zeneca Limited |
Substituted aryl and heteroaryl compounds as E-type prostaglandin antagonists
|
EP0783577B1
(en)
*
|
1995-07-26 |
2008-07-09 |
AstraZeneca AB |
Chimeric receptors and methods for identifying compounds active at metabotropic glutamate receptors and the use of such compounds in the treatment of neurological disorders and diseases
|
EP0788353A1
(en)
|
1995-09-18 |
1997-08-13 |
Ligand Pharmaceuticals, Inc. |
Ppar gamma antagonists for treating obesity
|
GB9624482D0
(en)
*
|
1995-12-18 |
1997-01-15 |
Zeneca Phaema S A |
Chemical compounds
|
US6716575B2
(en)
|
1995-12-18 |
2004-04-06 |
Sugen, Inc. |
Diagnosis and treatment of AUR1 and/or AUR2 related disorders
|
US7119174B2
(en)
|
1995-12-18 |
2006-10-10 |
Sugen, Inc. |
Diagnosis and treatment of AUR1 and/or AUR2 related disorders
|
US6184225B1
(en)
|
1996-02-13 |
2001-02-06 |
Zeneca Limited |
Quinazoline derivatives as VEGF inhibitors
|
GB9603095D0
(en)
*
|
1996-02-14 |
1996-04-10 |
Zeneca Ltd |
Quinazoline derivatives
|
GB9603097D0
(en)
*
|
1996-02-14 |
1996-04-10 |
Zeneca Ltd |
Quinazoline compounds
|
DE69709319T2
(de)
|
1996-03-05 |
2002-08-14 |
Astrazeneca Ab |
4-anilinochinazolin derivate
|
CN1254465C
(zh)
*
|
1996-04-09 |
2006-05-03 |
Nps医药公司 |
钙代谢化合物
|
US6818660B2
(en)
|
1996-04-09 |
2004-11-16 |
Nps Pharmaceuticals, Inc. |
Calcilytic compounds
|
BR9708640B1
(pt)
|
1996-04-12 |
2013-06-11 |
|
inibidores irreversÍveis de tirosina-cinases e composiÇço farmacÊutica compreendendo os mesmo.
|
GB9607729D0
(en)
*
|
1996-04-13 |
1996-06-19 |
Zeneca Ltd |
Quinazoline derivatives
|
GB9707800D0
(en)
|
1996-05-06 |
1997-06-04 |
Zeneca Ltd |
Chemical compounds
|
US6297198B1
(en)
|
1996-05-14 |
2001-10-02 |
Syngenta Participations Ag |
Isoxazole derivatives and their use as herbicides
|
US6696448B2
(en)
|
1996-06-05 |
2004-02-24 |
Sugen, Inc. |
3-(piperazinylbenzylidenyl)-2-indolinone compounds and derivatives as protein tyrosine kinase inhibitors
|
US6191131B1
(en)
|
1997-07-23 |
2001-02-20 |
Dupont Pharmaceuticals Company |
Azolo triazines and pyrimidines
|
US6313124B1
(en)
|
1997-07-23 |
2001-11-06 |
Dupont Pharmaceuticals Company |
Tetrazine bicyclic compounds
|
US6060478A
(en)
*
|
1996-07-24 |
2000-05-09 |
Dupont Pharmaceuticals |
Azolo triazines and pyrimidines
|
US6124289A
(en)
*
|
1996-07-24 |
2000-09-26 |
Dupont Pharmaceuticals Co. |
Azolo triazines and pyrimidines
|
US7094782B1
(en)
|
1996-07-24 |
2006-08-22 |
Bristol-Myers Squibb Company |
Azolo triazines and pyrimidines
|
JP3243733B2
(ja)
*
|
1996-08-07 |
2002-01-07 |
雪印乳業株式会社 |
新規イソキノリン誘導体
|
US6682921B1
(en)
|
1996-08-21 |
2004-01-27 |
New York University |
Crystals of the tyrosine kinase domain of non-insulin receptor tyrosine kinases
|
ES2297864T3
(es)
|
1996-08-23 |
2008-05-01 |
Novartis Ag |
Pirrolopirimidinas sustituidas y procesos para su preparacion.
|
US6004967A
(en)
*
|
1996-09-13 |
1999-12-21 |
Sugen, Inc. |
Psoriasis treatment with quinazoline compounds
|
GB9718972D0
(en)
*
|
1996-09-25 |
1997-11-12 |
Zeneca Ltd |
Chemical compounds
|
AU733551B2
(en)
|
1996-09-25 |
2001-05-17 |
Astrazeneca Ab |
Qinoline derivatives inhibiting the effect of growth factors such as VEGF
|
CN1169795C
(zh)
*
|
1996-10-01 |
2004-10-06 |
协和发酵工业株式会社 |
环胺取代的含氮杂环化合物及其组合物
|
ATE291022T1
(de)
|
1996-10-02 |
2005-04-15 |
Novartis Pharma Gmbh |
Pyrimiderivate und verfahren zu ihrer herstellung
|
US5827898A
(en)
*
|
1996-10-07 |
1998-10-27 |
Shaman Pharmaceuticals, Inc. |
Use of bisphenolic compounds to treat type II diabetes
|
US6225318B1
(en)
|
1996-10-17 |
2001-05-01 |
Pfizer Inc |
4-aminoquinazolone derivatives
|
EP0837063A1
(en)
*
|
1996-10-17 |
1998-04-22 |
Pfizer Inc. |
4-Aminoquinazoline derivatives
|
TW483881B
(en)
|
1996-12-03 |
2002-04-21 |
Nps Pharma Inc |
Calcilytic compounds
|
US7202261B2
(en)
|
1996-12-03 |
2007-04-10 |
Nps Pharmaceuticals, Inc. |
Calcilytic compounds
|
US6498163B1
(en)
|
1997-02-05 |
2002-12-24 |
Warner-Lambert Company |
Pyrido[2,3-D]pyrimidines and 4-aminopyrimidines as inhibitors of cellular proliferation
|
BR9807305A
(pt)
*
|
1997-02-05 |
2000-05-02 |
Warner Lambert Co |
Pirido [2,3-d] pirimidinas e 4-aminopirimidinas como inibidores de proliferação celular.
|
EP1806348A3
(en)
*
|
1997-02-05 |
2008-01-02 |
Warner-Lambert Company LLC |
Pyrido [2, 3 -d] pyrimidines and 4-amino-primidines as inhibitors of cellular proliferation
|
US6818440B2
(en)
|
1997-04-28 |
2004-11-16 |
Sugen, Inc. |
Diagnosis and treatment of alk-7 related disorders
|
AR012634A1
(es)
|
1997-05-02 |
2000-11-08 |
Sugen Inc |
Compuesto basado en quinazolina, composicion famaceutica que lo comprende, metodo para sintetizarlo, su uso, metodos de modulacion de la funcion deserina/treonina proteinaquinasa con dicho compuesto y metodo in vitro para identificar compuestos que modulan dicha funcion
|
US6486185B1
(en)
|
1997-05-07 |
2002-11-26 |
Sugen, Inc. |
3-heteroarylidene-2-indolinone protein kinase inhibitors
|
US6316429B1
(en)
|
1997-05-07 |
2001-11-13 |
Sugen, Inc. |
Bicyclic protein kinase inhibitors
|
US6316479B1
(en)
|
1997-05-19 |
2001-11-13 |
Sugen, Inc. |
Isoxazole-4-carboxamide compounds active against protein tryosine kinase related disorders
|
US6228641B1
(en)
|
1997-05-20 |
2001-05-08 |
Sugen, Inc. |
Diagnosis and treatment of PTP04 related disorders
|
US6245760B1
(en)
*
|
1997-05-28 |
2001-06-12 |
Aventis Pharmaceuticals Products, Inc |
Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases
|
US6180632B1
(en)
*
|
1997-05-28 |
2001-01-30 |
Aventis Pharmaceuticals Products Inc. |
Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases
|
WO1998054156A1
(en)
*
|
1997-05-28 |
1998-12-03 |
Rhone-Poulenc Rorer Pharmaceuticals, Inc. |
QUINOLINE AND QUINOXALINE COMPOUNDS WHICH INHIBIT PLATELET-DERIVED GROWTH FACTOR AND/OR P56lck TYROSINE KINASES
|
US6159978A
(en)
*
|
1997-05-28 |
2000-12-12 |
Aventis Pharmaceuticals Product, Inc. |
Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases
|
US6342593B1
(en)
|
1997-06-11 |
2002-01-29 |
Sugen, Inc. |
Diagnosis and treatment of ALP related disorders
|
US6987113B2
(en)
|
1997-06-11 |
2006-01-17 |
Sugen, Inc. |
Tyrosine kinase inhibitors
|
US7115710B2
(en)
|
1997-06-11 |
2006-10-03 |
Sugen, Inc. |
Diagnosis and treatment of PTP related disorders
|
US6388063B1
(en)
|
1997-06-18 |
2002-05-14 |
Sugen, Inc. |
Diagnosis and treatment of SAD related disorders
|
US6376670B1
(en)
|
1997-06-19 |
2002-04-23 |
Sepracor Inc. |
Quinoline-indole antimicrobial agents, uses and compositions related thereto
|
US6207679B1
(en)
|
1997-06-19 |
2001-03-27 |
Sepracor, Inc. |
Antimicrobial agents uses and compositions related thereto
|
WO1998057931A2
(en)
|
1997-06-19 |
1998-12-23 |
Sepracor Inc. |
Quinoline-indole antimicrobial agents, uses and compositions related thereto
|
US6103905A
(en)
*
|
1997-06-19 |
2000-08-15 |
Sepracor, Inc. |
Quinoline-indole antimicrobial agents, uses and compositions related thereto
|
US6114371A
(en)
*
|
1997-06-20 |
2000-09-05 |
Sugen, Inc. |
3-(cyclohexanoheteroarylidenyl)-2-indolinone protein tyrosine kinase inhibitors
|
US6313158B1
(en)
|
1997-06-20 |
2001-11-06 |
Sugen, Inc. |
Bioavailability of 3-heteroarylidenyl-2-indolinones active as protein tyrosine kinase inhibitors
|
US6130238A
(en)
*
|
1997-06-20 |
2000-10-10 |
Sugen, Inc. |
3-(cyclohexanoheteroarylidenyl)-2-indolinone protein tyrosine kinase inhibitors
|
US6051593A
(en)
*
|
1997-06-20 |
2000-04-18 |
Sugen, Inc. |
3-(cycloalkanoheteroarylidenyl)-2- indolinone protein tyrosine kinase inhibitors
|
US6235769B1
(en)
|
1997-07-03 |
2001-05-22 |
Sugen, Inc. |
Methods of preventing and treating neurological disorders with compounds that modulate the function of the C-RET receptor protein tyrosine kinase
|
US7098025B1
(en)
|
1997-07-25 |
2006-08-29 |
Ligand Pharmaceuticals Incorporated |
Human peroxisome proliferator activated receptor gamma (pparγ) gene regulatory sequences and uses therefor
|
WO1999007701A1
(en)
|
1997-08-05 |
1999-02-18 |
Sugen, Inc. |
Tricyclic quinoxaline derivatives as protein tyrosine kinase inhibitors
|
NZ502704A
(en)
*
|
1997-08-20 |
2002-06-28 |
Warner Lambert Co |
Naphthyridinones and pharmaceuticals thereof and their use in inhibiting cellular proliferation and protein tyrosine kinase or cell cycle kinase enzymatic activity
|
AU8816298A
(en)
|
1997-08-22 |
1999-03-16 |
Zeneca Limited |
Oxindolylquinazoline derivatives as angiogenesis inhibitors
|
RU2230553C2
(ru)
*
|
1997-09-26 |
2004-06-20 |
Центарис АГ |
Способ модулирования функции серин/треонин протеинкиназы соединением на основе азабензимидазола, способ идентификации соединений, модулирующих функцию серин/треонин протеинкиназы, способ профилактики или лечения патологических состояний в организме, соединение на основе азабензимидазола, способ его синтеза и фармацевтическая композиция
|
US6133305A
(en)
|
1997-09-26 |
2000-10-17 |
Sugen, Inc. |
3-(substituted)-2-indolinones compounds and use thereof as inhibitors of protein kinase activity
|
CA2304466A1
(en)
|
1997-10-06 |
1999-04-15 |
Basf Aktiengesellschaft |
Indeno[1,2-c]pyrazole derivatives for inhibiting tyrosine kinase activity
|
DE69818083T2
(de)
|
1997-10-06 |
2004-07-08 |
Abbott Gmbh & Co. Kg |
INDENO[1,2-c]-,NAPHTHO[1,2-C]-UND BENZO[6,7]CYCLOHEPTA[1,2-c]PYRAZOLDERIVATE
|
UA71555C2
(en)
|
1997-10-06 |
2004-12-15 |
Zentaris Gmbh |
Methods for modulating function of serine/threonine protein kinases by 5-azaquinoline derivatives
|
US6225346B1
(en)
|
1997-10-24 |
2001-05-01 |
Sugen, Inc. |
Tyrphostin like compounds
|
CA2306082A1
(en)
*
|
1997-10-27 |
1999-05-06 |
Agouron Pharmaceuticals, Inc. |
Substituted 4-amino-thiazol-2-y compounds as cdks inhibitors
|
EP1215208B1
(en)
*
|
1997-10-27 |
2006-07-12 |
Agouron Pharmaceuticals, Inc. |
4-Aminothiazole derivatives, their preparation and their use as inhibitors of cyclin-dependent kinases
|
US6150379A
(en)
*
|
1997-11-26 |
2000-11-21 |
Axys Pharmaceuticals, Inc. |
Compounds and compositions as anticoagulants
|
US5932580A
(en)
*
|
1997-12-01 |
1999-08-03 |
Yissum Research And Development Company Of The Hebrew University Of Jerusalem |
PDGF receptor kinase inhibitory compounds their preparation and compositions
|
WO1999032482A1
(en)
*
|
1997-12-19 |
1999-07-01 |
Eli Lilly And Company |
Hypoglycemic imidazoline compounds
|
WO1999037787A2
(en)
|
1998-01-21 |
1999-07-29 |
Sugen, Inc. |
Human orthologues of wart
|
US6531502B1
(en)
|
1998-01-21 |
2003-03-11 |
Sugen, Inc. |
3-Methylidenyl-2-indolinone modulators of protein kinase
|
US6756367B2
(en)
*
|
1998-02-03 |
2004-06-29 |
Novartis Ag |
Benzo-oxadiazoles, -thiadiazoles and -1,4-diazines, pharmaceutical compositions containing them and a process for preparing them
|
AU3363599A
(en)
*
|
1998-03-26 |
1999-10-18 |
Max-Planck Institut Fur Biochemie |
Heterocyclic families of compounds for the modulation of tyrosine protein kinase
|
US6423716B1
(en)
|
1998-03-31 |
2002-07-23 |
Kyowa Hakko Kogyo Co., Ltd. |
Nitrogenous heterocyclic compounds
|
US6514981B1
(en)
|
1998-04-02 |
2003-02-04 |
Sugen, Inc. |
Methods of modulating tyrosine protein kinase function with indolinone compounds
|
WO1999052895A1
(en)
|
1998-04-10 |
1999-10-21 |
Japan Tobacco Inc. |
Amidine compounds
|
DK1073723T3
(da)
|
1998-04-14 |
2006-01-02 |
Sugen Inc |
STE20-relaterede proteinkinaser
|
US6569868B2
(en)
|
1998-04-16 |
2003-05-27 |
Sugen, Inc. |
2-indolinone derivatives as modulators of protein kinase activity
|
US6706721B1
(en)
|
1998-04-29 |
2004-03-16 |
Osi Pharmaceuticals, Inc. |
N-(3-ethynylphenylamino)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine mesylate anhydrate and monohydrate
|
TR200003429T2
(tr)
|
1998-05-26 |
2001-07-23 |
Warner-Lambert Company |
Hücresel çoğalma inhibitörleri olarak bisiklik pirimidinler ve bisiklik 3,4-dihidropirimidinler.
|
EP1801112A1
(en)
*
|
1998-05-26 |
2007-06-27 |
Warner-Lambert Company LLC |
Bicyclic pyrimidines and bicyclic 3,4-dihydropyrimidines as inhibitors of cellular proliferation
|
US6395734B1
(en)
|
1998-05-29 |
2002-05-28 |
Sugen, Inc. |
Pyrrole substituted 2-indolinone protein kinase inhibitors
|
US6878716B1
(en)
|
1998-06-02 |
2005-04-12 |
Osi Pharmaceuticals, Inc. |
Compounds specific to adenosine A1 receptor and uses thereof
|
ID27600A
(id)
|
1998-06-02 |
2001-04-12 |
Osi Pharm Inc |
KOMPOSISI PIROLO (2,3d) PIRIMIDIN DAN PENGGUNAANNYA
|
US6686366B1
(en)
|
1998-06-02 |
2004-02-03 |
Osi Pharmaceuticals, Inc. |
Compounds specific to adenosine A3 receptor and uses thereof
|
UA60365C2
(uk)
|
1998-06-04 |
2003-10-15 |
Пфайзер Продактс Інк. |
Похідні ізотіазолу, спосіб їх одержання, фармацевтична композиція та спосіб лікування гіперпроліферативного захворювання у ссавця
|
AU4676999A
(en)
*
|
1998-06-12 |
1999-12-30 |
Ligand Pharmaceuticals, Inc. |
Treatment of anti-estrogen resistant breast cancer using rxr modulators
|
US6184226B1
(en)
|
1998-08-28 |
2001-02-06 |
Scios Inc. |
Quinazoline derivatives as inhibitors of P-38 α
|
AU5438499A
(en)
|
1998-08-29 |
2000-03-21 |
Astrazeneca Ab |
Pyrimidine compounds
|
WO2000012485A1
(en)
|
1998-08-29 |
2000-03-09 |
Astrazeneca Ab |
Pyrimidine compounds
|
CA2342222A1
(en)
|
1998-08-31 |
2000-03-09 |
Sugen, Inc. |
Geometrically restricted 2-indolinone derivatives as modulators of protein kinase activity
|
AU760008B2
(en)
|
1998-09-08 |
2003-05-08 |
Agouron Pharmaceuticals, Inc. |
Modifications of the VEGF receptor-2 protein and methods of use
|
US6680335B2
(en)
|
1998-09-28 |
2004-01-20 |
Sugen, Inc. |
Methods of modulating protein tyrosine kinase function with substituted indolinone compounds
|
ATE294796T1
(de)
|
1998-10-08 |
2005-05-15 |
Astrazeneca Ab |
Chinazolin derivate
|
GB9828511D0
(en)
|
1998-12-24 |
1999-02-17 |
Zeneca Ltd |
Chemical compounds
|
EP1630559A3
(en)
*
|
1998-12-30 |
2006-06-07 |
Sugen, Inc. |
PYK2 (RAFTK) and inflammation
|
UA71945C2
(en)
|
1999-01-27 |
2005-01-17 |
Pfizer Prod Inc |
Substituted bicyclic derivatives being used as anticancer agents
|
JP3270834B2
(ja)
|
1999-01-27 |
2002-04-02 |
ファイザー・プロダクツ・インク |
抗がん剤として有用なヘテロ芳香族二環式誘導体
|
ES2351699T3
(es)
|
1999-02-10 |
2011-02-09 |
Astrazeneca Ab |
Derivados de quinazolina como inhibidores de la angiogénesis e intermedios de los mismos.
|
GB9905075D0
(en)
|
1999-03-06 |
1999-04-28 |
Zeneca Ltd |
Chemical compounds
|
US6689806B1
(en)
|
1999-03-24 |
2004-02-10 |
Sugen, Inc. |
Indolinone compounds as kinase inhibitors
|
GB9907658D0
(en)
|
1999-04-06 |
1999-05-26 |
Zeneca Ltd |
Chemical compounds
|
GB9910579D0
(en)
|
1999-05-08 |
1999-07-07 |
Zeneca Ltd |
Chemical compounds
|
GB9910580D0
(en)
|
1999-05-08 |
1999-07-07 |
Zeneca Ltd |
Chemical compounds
|
UA71971C2
(en)
*
|
1999-06-04 |
2005-01-17 |
Agoron Pharmaceuticals Inc |
Diaminothiazoles, composition based thereon, a method for modulation of protein kinases activity, a method for the treatment of diseases mediated by protein kinases
|
GB9919778D0
(en)
|
1999-08-21 |
1999-10-27 |
Zeneca Ltd |
Chemical compounds
|
US6921763B2
(en)
|
1999-09-17 |
2005-07-26 |
Abbott Laboratories |
Pyrazolopyrimidines as therapeutic agents
|
CZ20021010A3
(cs)
|
1999-09-21 |
2002-06-12 |
Astrazeneca Ab |
Nové sloučeniny chinazolinu a farmaceutické kompozice, které je obsahují
|
US6794393B1
(en)
*
|
1999-10-19 |
2004-09-21 |
Merck & Co., Inc. |
Tyrosine kinase inhibitors
|
DZ3223A1
(fr)
*
|
1999-10-19 |
2001-04-26 |
Merck & Co Inc |
Inhibiteurs de tyrosine kinases
|
DE60018782T2
(de)
*
|
1999-10-19 |
2006-04-06 |
Merck & Co., Inc. |
Tyrosin kinase inhibitoren
|
CA2388599A1
(en)
|
1999-10-22 |
2001-05-03 |
Pharmacia & Upjohn Company |
Drosophila g protein coupled receptors, nucleic acids, and methods related to the same
|
KR100849151B1
(ko)
*
|
1999-11-05 |
2008-07-30 |
아스트라제네카 아베 |
Vegf 억제제로서의 퀴나졸린 유도체
|
US7087613B2
(en)
|
1999-11-11 |
2006-08-08 |
Osi Pharmaceuticals, Inc. |
Treating abnormal cell growth with a stable polymorph of N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine hydrochloride
|
UA74803C2
(uk)
|
1999-11-11 |
2006-02-15 |
Осі Фармасьютікалз, Інк. |
Стійкий поліморф гідрохлориду n-(3-етинілфеніл)-6,7-біс(2-метоксіетокси)-4-хіназолінаміну, спосіб його одержання (варіанти) та фармацевтичне застосування
|
CO5261573A1
(es)
|
1999-11-19 |
2003-03-31 |
Novartis Ag |
Derivados de benzoxa y bezotiazol, compuesto y composicion farmaceutica que los contiene y proceso para la preparacion de la mencionada composicion
|
US6878733B1
(en)
|
1999-11-24 |
2005-04-12 |
Sugen, Inc. |
Formulations for pharmaceutical agents ionizable as free acids or free bases
|
UA75055C2
(uk)
*
|
1999-11-30 |
2006-03-15 |
Пфайзер Продактс Інк. |
Похідні бензоімідазолу, що використовуються як антипроліферативний засіб, фармацевтична композиція на їх основі
|
US6680322B2
(en)
|
1999-12-02 |
2004-01-20 |
Osi Pharmaceuticals, Inc. |
Compounds specific to adenosine A1 receptors and uses thereof
|
US6664252B2
(en)
|
1999-12-02 |
2003-12-16 |
Osi Pharmaceuticals, Inc. |
4-aminopyrrolo[2,3-d]pyrimidine compounds specific to adenosine A2a receptor and uses thereof
|
US7160890B2
(en)
*
|
1999-12-02 |
2007-01-09 |
Osi Pharmaceuticals, Inc. |
Compounds specific to adenosine A3 receptor and uses thereof
|
AU784266B2
(en)
|
1999-12-22 |
2006-03-02 |
Sugen, Inc. |
Indolinone derivatives for modulation of c-kit tyrosine kinase
|
EP1294709A2
(en)
|
2000-01-28 |
2003-03-26 |
AstraZeneca AB |
Quinoline derivatives and their use as aurora 2 kinase inhibitors
|
CN1422262A
(zh)
|
2000-02-07 |
2003-06-04 |
艾博特股份有限两合公司 |
2-苯并噻唑基脲衍生物及其作为蛋白激酶抑制剂的应用
|
EP1255752B1
(en)
*
|
2000-02-15 |
2007-08-08 |
Sugen, Inc. |
Pyrrole substituted 2-indolinone protein kinase inhibitors
|
US6420382B2
(en)
*
|
2000-02-25 |
2002-07-16 |
Merck & Co., Inc. |
Tyrosine kinase inhibitors
|
US6313138B1
(en)
|
2000-02-25 |
2001-11-06 |
Merck & Co., Inc. |
Tyrosine kinase inhibitors
|
JP2003523390A
(ja)
*
|
2000-02-25 |
2003-08-05 |
メルク エンド カムパニー インコーポレーテッド |
チロシンキナーゼ阻害薬
|
ES2243461T3
(es)
|
2000-02-28 |
2005-12-01 |
Sugen, Inc. |
Compuestos de 3-(pirolillactona) -2-indolinona como inhibidores quinasa.
|
GB0004888D0
(en)
|
2000-03-01 |
2000-04-19 |
Astrazeneca Uk Ltd |
Chemical compounds
|
GB0004886D0
(en)
|
2000-03-01 |
2000-04-19 |
Astrazeneca Uk Ltd |
Chemical compounds
|
GB0004890D0
(en)
|
2000-03-01 |
2000-04-19 |
Astrazeneca Uk Ltd |
Chemical compounds
|
GB0004887D0
(en)
|
2000-03-01 |
2000-04-19 |
Astrazeneca Uk Ltd |
Chemical compounds
|
US7235551B2
(en)
*
|
2000-03-02 |
2007-06-26 |
Smithkline Beecham Corporation |
1,5-disubstituted-3,4-dihydro-1h-pyrimido[4,5-d]pyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases
|
GB0007371D0
(en)
|
2000-03-28 |
2000-05-17 |
Astrazeneca Uk Ltd |
Chemical compounds
|
US6511984B2
(en)
|
2000-03-30 |
2003-01-28 |
Pfizer Inc. |
Neuropeptide Y antagonists
|
MXPA02009891A
(es)
|
2000-04-07 |
2003-03-27 |
Astrazeneca Ab |
Compuestos de quinazolina.
|
MXPA02010222A
(es)
|
2000-04-18 |
2003-05-23 |
Agouron Pharma |
Pirazoles para inhibir proteina cinasa.
|
MY128449A
(en)
|
2000-05-24 |
2007-02-28 |
Sugen Inc |
Prodrugs of 3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives
|
US6706709B2
(en)
|
2000-06-02 |
2004-03-16 |
Sugen, Inc. |
Indolinone derivatives as protein kinase/phosphatase inhibitors
|
UA73993C2
(uk)
|
2000-06-06 |
2005-10-17 |
Астразенека Аб |
Хіназолінові похідні для лікування пухлин та фармацевтична композиція
|
PE20020063A1
(es)
|
2000-06-20 |
2002-01-30 |
Upjohn Co |
Bis-arilsulfonas como ligandos del receptor de 5-ht
|
US6586592B2
(en)
|
2000-06-20 |
2003-07-01 |
Pharmacia & Upjohn Company |
Bis-arylsulfones
|
PL360439A1
(en)
|
2000-06-28 |
2004-09-06 |
Astrazeneca Ab |
Substituted quinazoline derivatives and their use as inhibitors
|
GB0016877D0
(en)
|
2000-07-11 |
2000-08-30 |
Astrazeneca Ab |
Chemical compounds
|
CN1252065C
(zh)
|
2000-08-09 |
2006-04-19 |
阿斯特拉曾尼卡有限公司 |
噌啉化合物
|
CA2415469A1
(en)
|
2000-08-09 |
2002-02-14 |
Astrazeneca Ab |
Quinoline derivatives having vegf inhibiting activity
|
IL154514A0
(en)
|
2000-08-18 |
2003-09-17 |
Millennium Pharm Inc |
Quinazoline derivatives and pharmaceutical compositions containing the same
|
PL202812B1
(pl)
|
2000-08-21 |
2009-07-31 |
Astrazeneca Ab |
Pochodna chinazoliny, jej kompozycja famaceutyczna oraz jej zastosowanie
|
US6756383B2
(en)
*
|
2000-09-01 |
2004-06-29 |
Chiron Corporation |
Heterocyclic derivatives of quinolinone benimidazoles
|
GB0021726D0
(en)
|
2000-09-05 |
2000-10-18 |
Astrazeneca Ab |
Chemical compounds
|
AP1666A
(en)
|
2000-09-11 |
2006-09-29 |
Chiron Corp |
Quinolinone derivatives as tyrosine kinase inhibitors.
|
FR2813791B1
(fr)
*
|
2000-09-14 |
2004-03-12 |
Lafon Labor |
Utilisation de 2- et 4-quinolones pour inhiber la neo-proliferation intimale
|
JP2004511479A
(ja)
|
2000-10-13 |
2004-04-15 |
アストラゼネカ アクチボラグ |
キナゾリン誘導体
|
US6939866B2
(en)
|
2000-10-13 |
2005-09-06 |
Astrazeneca Ab |
Quinazoline derivatives
|
JP2004511541A
(ja)
*
|
2000-10-17 |
2004-04-15 |
メルク エンド カムパニー インコーポレーテッド |
チロシンキナーゼ活性を有する経***性塩
|
TWI304061B
(en)
|
2000-10-20 |
2008-12-11 |
Eisai R&D Man Co Ltd |
Nitrogen-containing aromatic ring derivatives
|
KR100850812B1
(ko)
*
|
2000-10-23 |
2008-08-06 |
스미스클라인 비참 코포레이션 |
신규 화합물
|
WO2002036587A2
(en)
|
2000-11-01 |
2002-05-10 |
Cor Therapeutics, Inc. |
Process for the production of 4-quinazolinylpiperazin-1-carboxylic acid phenylamides
|
WO2002036570A1
(en)
*
|
2000-11-02 |
2002-05-10 |
Astrazeneca Ab |
4-substituted quinolines as antitumor agents
|
JP2004514718A
(ja)
*
|
2000-11-02 |
2004-05-20 |
アストラゼネカ アクチボラグ |
抗癌剤としての置換キノリン類
|
US6680324B2
(en)
*
|
2000-12-01 |
2004-01-20 |
Osi Pharmaceuticals, Inc. |
Compounds specific to adenosine A1 receptors and uses thereof
|
US6673802B2
(en)
|
2000-12-01 |
2004-01-06 |
Osi Pharmaceuticals, Inc. |
Compounds specific to adenosine A3 receptor and uses thereof
|
US6582919B2
(en)
|
2001-06-11 |
2003-06-24 |
Response Genetics, Inc. |
Method of determining epidermal growth factor receptor and HER2-neu gene expression and correlation of levels thereof with survival rates
|
AR042586A1
(es)
*
|
2001-02-15 |
2005-06-29 |
Sugen Inc |
3-(4-amidopirrol-2-ilmetiliden)-2-indolinona como inhibidores de la protein quinasa; sus composiciones farmaceuticas; un metodo para la modulacion de la actividad catalitica de la proteinquinasa; un metodo para tratar o prevenir una afeccion relacionada con la proteinquinasa
|
GB0103926D0
(en)
|
2001-02-17 |
2001-04-04 |
Astrazeneca Ab |
Chemical compounds
|
MXPA03008560A
(es)
|
2001-03-22 |
2004-06-30 |
Abbot Gmbh & Co Kg |
Pirazolopirimidinas como agentes terapeuticos.
|
US7141577B2
(en)
|
2001-04-19 |
2006-11-28 |
Astrazeneca Ab |
Quinazoline derivatives
|
US6599902B2
(en)
|
2001-05-30 |
2003-07-29 |
Sugen, Inc. |
5-aralkysufonyl-3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives as kinase inhibitors
|
GB0113041D0
(en)
|
2001-05-30 |
2001-07-18 |
Astrazeneca Ab |
Chemical compounds
|
EP1408980A4
(en)
|
2001-06-21 |
2004-10-20 |
Ariad Pharma Inc |
NEW QUINAZOLINES AND THEIR USE
|
US8124625B2
(en)
*
|
2001-09-14 |
2012-02-28 |
Shionogi & Co., Ltd. |
Method of enhancing the expression of apolipoprotein AI using olefin derivatives
|
US6765012B2
(en)
|
2001-09-27 |
2004-07-20 |
Allergan, Inc. |
3-(Arylamino)methylene-1,3-dihydro-2H-indol-2-ones as kinase inhibitors
|
US6559173B1
(en)
|
2001-09-27 |
2003-05-06 |
Allergan, Inc. |
3-(heteroarylamino)methylene-1,3-dihydro-2H-indol-2-ones as kinase inhibitors
|
EP1434774A1
(en)
|
2001-10-10 |
2004-07-07 |
Sugen, Inc. |
3-(4-substituted heterocyclyl)-pyrrol-2-ylmethylidene)-2-indolinone derivatives as protein kinase inhibitors
|
US7169788B2
(en)
*
|
2001-10-30 |
2007-01-30 |
Merck & Co., Inc. |
Tyrosine kinase inhibitors
|
US7504407B2
(en)
|
2001-11-30 |
2009-03-17 |
Osi Pharmaceuticals, Inc. |
Compounds specific to adenosine A1 and A3 receptors and uses thereof
|
CN1816551A
(zh)
*
|
2001-12-20 |
2006-08-09 |
Osi药物公司 |
吡咯并嘧啶A2b选择性拮抗剂化合物,它们的合成及用途
|
EA007468B1
(ru)
|
2001-12-20 |
2006-10-27 |
Оси Фармасьютикалз, Инк. |
Пиримидиновые соединения, относящиеся к a-селективным антагонистам, их синтез и применение
|
AU2002353196B2
(en)
|
2001-12-24 |
2008-01-17 |
Astrazeneca Ab |
Substituted quinazoline derivatives as inhibitors of aurora kinases
|
KR20060111716A
(ko)
|
2002-01-22 |
2006-10-27 |
워너-램버트 캄파니 엘엘씨 |
2-(피리딘-2-일아미노)-피리도[2,3-d]피리미딘-7-온
|
PL371486A1
(en)
|
2002-02-01 |
2005-06-13 |
Astrazeneca Ab |
Quinazoline compounds
|
GB0205690D0
(en)
|
2002-03-09 |
2002-04-24 |
Astrazeneca Ab |
Chemical compounds
|
GB0205688D0
(en)
|
2002-03-09 |
2002-04-24 |
Astrazeneca Ab |
Chemical compounds
|
AU2003208479A1
(en)
|
2002-03-09 |
2003-09-22 |
Astrazeneca Ab |
4- imidazolyl substuited pyrimidine derivatives with cdk inhibitiory activity
|
GB0205693D0
(en)
|
2002-03-09 |
2002-04-24 |
Astrazeneca Ab |
Chemical compounds
|
EP1492784A4
(en)
|
2002-03-28 |
2006-03-29 |
Merck & Co Inc |
SUBSTITUTED 2,3-DIPHENYLPYRIDINES
|
US6924285B2
(en)
|
2002-03-30 |
2005-08-02 |
Boehringer Ingelheim Pharma Gmbh & Co. |
Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them
|
US6541504B1
(en)
|
2002-04-03 |
2003-04-01 |
Allergan Sales, Llc |
(3Z)-3-(2,3-dihydro-1H-inden-1-ylidene)-1,3-dihydro-2H-indol-2-ones as kinase inhibitors
|
EP1499320B1
(en)
*
|
2002-04-19 |
2007-08-22 |
Smithkline Beecham Corporation |
Novel compounds
|
EA008770B1
(ru)
*
|
2002-05-15 |
2007-08-31 |
Янссен Фамацевтика Н.В. |
N-замещенные трициклические 3-аминопиразолы в качестве ингибиторов pdgf рецептора
|
WO2004004732A1
(en)
*
|
2002-07-09 |
2004-01-15 |
Astrazeneca Ab |
Quinazoline derivatives for use in the treatment of cancer
|
GB0215823D0
(en)
*
|
2002-07-09 |
2002-08-14 |
Astrazeneca Ab |
Quinazoline derivatives
|
US7169936B2
(en)
|
2002-07-23 |
2007-01-30 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Indolinone derivatives substituted in the 6-position, their preparation and their use as medicaments
|
US7514468B2
(en)
|
2002-07-23 |
2009-04-07 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Indolinone derivatives substituted in the 6 position, the preparation thereof and their use as pharmaceutical compositions
|
MXPA05000950A
(es)
|
2002-07-25 |
2005-05-16 |
Pfizer Prod Inc |
Derivados de isotiazol utiles como agentes anticancerosos.
|
EP1542989B1
(en)
*
|
2002-07-31 |
2007-04-18 |
Critical Outcome Technologies, Inc. |
Protein tyrosine kinase inhibitors
|
IL166528A0
(en)
|
2002-08-02 |
2006-01-15 |
Ab Science |
2-(3-aminoaryl)amino-4-aryl-thiazoles and their use as c-kit inhibitors
|
US8450302B2
(en)
|
2002-08-02 |
2013-05-28 |
Ab Science |
2-(3-aminoaryl) amino-4-aryl-thiazoles and their use as c-kit inhibitors
|
CA2496164C
(en)
|
2002-08-23 |
2010-11-09 |
Chiron Corporation |
Benzimidazole quinolinones and uses thereof
|
US7825132B2
(en)
|
2002-08-23 |
2010-11-02 |
Novartis Vaccines And Diagnostics, Inc. |
Inhibition of FGFR3 and treatment of multiple myeloma
|
CA2542007C
(en)
*
|
2002-10-09 |
2010-06-29 |
Wayne R. Danter |
Protein tyrosine kinase inhibitors
|
GB0225548D0
(en)
|
2002-11-01 |
2002-12-11 |
Glaxo Group Ltd |
Compounds
|
GB0225579D0
(en)
*
|
2002-11-02 |
2002-12-11 |
Astrazeneca Ab |
Chemical compounds
|
CN1708306A
(zh)
*
|
2002-11-04 |
2005-12-14 |
Nps制药公司 |
作为钙阻滞剂的喹唑啉酮化合物
|
DK1562955T3
(da)
|
2002-11-04 |
2008-06-02 |
Astrazeneca Ab |
Quinazolinderivater som Src-tyrosinkinaseinhibitorer
|
WO2004041256A2
(en)
*
|
2002-11-08 |
2004-05-21 |
Novo Nordisk A/S |
Safe chemical uncouplers for the treatment of obesity
|
BR0316229A
(pt)
|
2002-11-13 |
2005-10-04 |
Chiron Corp |
Métodos de tratamento de câncer e métodos relacionados
|
US6747025B1
(en)
|
2002-11-27 |
2004-06-08 |
Allergan, Inc. |
Kinase inhibitors for the treatment of disease
|
US6699863B1
(en)
|
2002-11-27 |
2004-03-02 |
Allergan, Inc. |
Kinase inhibitors for the treatment of disease
|
PL379330A1
(pl)
|
2002-12-20 |
2006-08-21 |
Pfizer Products Inc. |
Pochodne pirymidyny dla leczenia nienormalnego wzrostu komórek
|
MY136174A
(en)
|
2002-12-24 |
2008-08-29 |
Astrazeneca Ab |
Phosphonooxy quinazoline derivatives and their pharmaceutical use
|
MXPA05008612A
(es)
*
|
2003-02-14 |
2005-12-05 |
Smithkline Beecham Corp |
Compuestos novedosos.
|
DK2476667T3
(da)
*
|
2003-02-26 |
2014-09-15 |
Sugen Inc |
Aminoheteroaryl-forbindelser som proteinkinase-inhibitorer
|
US7157577B2
(en)
|
2003-03-07 |
2007-01-02 |
Sugen Inc. |
5-sulfonamido-substituted indolinone compounds as protein kinase inhibitors
|
GB0309850D0
(en)
|
2003-04-30 |
2003-06-04 |
Astrazeneca Ab |
Quinazoline derivatives
|
GB0311274D0
(en)
|
2003-05-16 |
2003-06-18 |
Astrazeneca Ab |
Chemical compounds
|
GB0311276D0
(en)
|
2003-05-16 |
2003-06-18 |
Astrazeneca Ab |
Chemical compounds
|
CA2525383C
(en)
|
2003-06-06 |
2012-03-06 |
Arexis Ab |
Use of heterocyclic compounds as scce inhibitors
|
WO2006074147A2
(en)
|
2005-01-03 |
2006-07-13 |
Myriad Genetics, Inc. |
Nitrogen containing bicyclic compounds and therapeutical use thereof
|
US8309562B2
(en)
*
|
2003-07-03 |
2012-11-13 |
Myrexis, Inc. |
Compounds and therapeutical use thereof
|
CA2531327A1
(en)
*
|
2003-07-03 |
2005-01-13 |
Myriad Genetics, Inc. |
Compounds and therapeutical use thereof
|
GB0317665D0
(en)
|
2003-07-29 |
2003-09-03 |
Astrazeneca Ab |
Qinazoline derivatives
|
EP1653946A4
(en)
|
2003-08-06 |
2007-04-04 |
Sugen Inc |
3-CYCLOPENTYLIDENE-1,3-DIHYDROINDOL-2-ONES GEOMETRICALLY LIMITED AS POWERFUL INHIBITORS OF PROTEIN KINASES
|
AU2004268614C1
(en)
|
2003-08-27 |
2010-10-28 |
Ophthotech Corporation |
Combination therapy for the treatment of ocular neovascular disorders
|
ATE395346T1
(de)
|
2003-09-16 |
2008-05-15 |
Astrazeneca Ab |
Chinazolinderivate als tyrosinkinaseinhibitoren
|
AU2004274227B2
(en)
|
2003-09-19 |
2008-04-24 |
Astrazeneca Ab |
Quinazoline derivatives
|
DE602004019135D1
(de)
*
|
2003-10-07 |
2009-03-05 |
Centelion |
Screeningverfahren für Kombinationen von biologischen Verbindungen
|
ATE465731T1
(de)
|
2003-10-23 |
2010-05-15 |
Ab Science |
2-aminoaryloxazol-verbindungen als tyrosinkinase- hemmer
|
JP4303726B2
(ja)
|
2003-11-11 |
2009-07-29 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
ウレア誘導体およびその製造方法
|
CN1914179A
(zh)
*
|
2003-11-13 |
2007-02-14 |
詹森药业有限公司 |
用于生物分子靶标识别的固定的n-取代的三环3-氨基吡唑类
|
GB0326459D0
(en)
|
2003-11-13 |
2003-12-17 |
Astrazeneca Ab |
Quinazoline derivatives
|
GB0330002D0
(en)
*
|
2003-12-24 |
2004-01-28 |
Astrazeneca Ab |
Quinazoline derivatives
|
BRPI0400869B8
(pt)
*
|
2004-03-02 |
2021-05-25 |
Univ Estadual Campinas Unicamp |
novos compostos derivados de 4-anilinoquinazolinas com propriedade inibidora de adenosinacinases
|
TW200528101A
(en)
|
2004-02-03 |
2005-09-01 |
Astrazeneca Ab |
Chemical compounds
|
BRPI0507891A
(pt)
|
2004-02-20 |
2007-07-24 |
Chiron Corp |
modulação dos processos inflamatório e metastático
|
ATE433979T1
(de)
|
2004-04-02 |
2009-07-15 |
Osi Pharm Inc |
Mit einem 6,6-bicyclischen ring substituierte heterobicyclische proteinkinaseinhibitoren
|
JP2008501628A
(ja)
*
|
2004-06-02 |
2008-01-24 |
武田薬品工業株式会社 |
インドール誘導体およびがんの治療用途
|
MY139689A
(en)
|
2004-07-20 |
2009-10-30 |
Osi Pharm Inc |
Imidazotriazines as protein kinase inhibitors
|
US8969379B2
(en)
|
2004-09-17 |
2015-03-03 |
Eisai R&D Management Co., Ltd. |
Pharmaceutical compositions of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7=methoxy-6-quinolinecarboxide
|
US20070197538A1
(en)
*
|
2004-10-07 |
2007-08-23 |
Mark Nesbit |
Anti-vascular and anti-proliferation methods, therapies, and combinations employing specific tyrosine kinase inhibitors
|
BRPI0516093A
(pt)
|
2004-10-12 |
2008-08-19 |
Astrazeneca Ab |
derivado de quinazolina, processo para a preparação do mesmo, composição farmacêutica, uso de um derivado de quinazolina, e, método para tratamento de distúrbios proliferativos celulares em um animal de sanque quente
|
US8093273B2
(en)
|
2004-10-20 |
2012-01-10 |
Resverlogix Corp. |
Flavanoids and isoflavanoids for the prevention and treatment of cardiovascular diseases
|
CN101124228B
(zh)
|
2004-12-14 |
2011-06-15 |
阿斯利康(瑞典)有限公司 |
用作抗肿瘤药物的吡唑并嘧啶化合物
|
US8258145B2
(en)
*
|
2005-01-03 |
2012-09-04 |
Myrexis, Inc. |
Method of treating brain cancer
|
PT1854789E
(pt)
|
2005-02-23 |
2013-10-23 |
Shionogi & Co |
Derivado de quinazolina possuindo actividade inibidora de tirosina-cinase
|
CA2599210A1
(en)
|
2005-02-26 |
2006-08-31 |
Astrazeneca Ab |
Quinazoline derivatives as tyrosine kinase inhibitors
|
JP2008531709A
(ja)
|
2005-03-01 |
2008-08-14 |
ワイス |
シンノリン化合物および肝臓x受容体調節物質としてのそれらの使用
|
PE20061193A1
(es)
*
|
2005-03-25 |
2006-12-02 |
Glaxo Group Ltd |
DERIVADOS DE 3,4-DIHIDROPIRIMIDO[4,5-d]PIRIMIDIN-2-[1H]-0NA COMO INHIBIDORES DE QUINASA p38
|
JP2008535822A
(ja)
*
|
2005-03-25 |
2008-09-04 |
グラクソ グループ リミテッド |
新規化合物
|
US7479558B2
(en)
*
|
2005-03-25 |
2009-01-20 |
Glaxo Group Limited |
Process for preparing pyrido[2,3-d]pyrimidin-7-one and 3,4-dihydropyrimido[4,5-d]pyrimidin-2(1H)-one derivatives
|
PE20100737A1
(es)
|
2005-03-25 |
2010-11-27 |
Glaxo Group Ltd |
Nuevos compuestos
|
MX2007012392A
(es)
|
2005-04-04 |
2007-12-05 |
Ab Science |
Derivados de oxazol sustituidos y su uso como inhibidores de tirosina cinasa.
|
ES2600460T3
(es)
|
2005-05-10 |
2017-02-09 |
Intermune, Inc. |
Derivados de piridona-2-ona como moduladores del sistema de proteína cinasa activada por estrés
|
BRPI0610360A2
(pt)
|
2005-05-13 |
2010-06-15 |
Novartis Ag |
métodos para tratar de cáncer resistente a fármaco
|
WO2006125130A1
(en)
|
2005-05-17 |
2006-11-23 |
Novartis Ag |
Methods for synthesizing heterocyclic compounds
|
SG154451A1
(en)
|
2005-05-23 |
2009-08-28 |
Novartis Ag |
Crystalline and other forms of 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1- yl)-1h-benzimidazol-2-yl]-1h-quinolin-2-one lactic acid salts
|
EP2314295B1
(en)
|
2005-07-29 |
2015-01-28 |
Resverlogix, Inc |
Pharmaceutical compositions for the prevention and treatment of complex diseases and their delivery by insertable medical devices
|
EP1925676A4
(en)
|
2005-08-02 |
2010-11-10 |
Eisai R&D Man Co Ltd |
TEST METHOD FOR THE EFFECT OF A VASCULARIZATION INHIBITOR
|
JP2009507032A
(ja)
|
2005-09-02 |
2009-02-19 |
アボット・ラボラトリーズ |
新規なイミダゾ系複素環
|
DE602006018331D1
(de)
|
2005-09-20 |
2010-12-30 |
Astrazeneca Ab |
4-(1h-indazol-5-ylamino)chinazolinverbindungen als inhibitoren der erbb-rezeptortyrosinkinase zur behandlung von krebs
|
US20080003219A1
(en)
*
|
2005-09-26 |
2008-01-03 |
Minu, L.L.C. |
Delivery of an ocular agent
|
KR20080049130A
(ko)
|
2005-09-30 |
2008-06-03 |
아스트라제네카 아베 |
세포 증식 억제 활성을 갖는 이미다조 [1,2-a] 피리딘
|
GB0519879D0
(en)
|
2005-09-30 |
2005-11-09 |
Astrazeneca Ab |
Chemical process
|
AR057960A1
(es)
|
2005-12-02 |
2007-12-26 |
Osi Pharm Inc |
Inhibidores de proteina quinasa biciclicos
|
US7465795B2
(en)
|
2005-12-20 |
2008-12-16 |
Astrazeneca Ab |
Compounds and uses thereof
|
CN104592128A
(zh)
|
2005-12-20 |
2015-05-06 |
阿斯利康(瑞典)有限公司 |
作为gabaa受体调节剂的取代的噌啉衍生物及其合成方法
|
US8367664B2
(en)
|
2006-01-24 |
2013-02-05 |
Allergan, Inc. |
Substituted 3-(5-membered unsaturated heterocyclyl-1, 3-dihydro-indol-2-one's and derivatives thereof as kinase inhibitors
|
UY30183A1
(es)
|
2006-03-02 |
2007-10-31 |
Astrazeneca Ab |
Derivados de quinolina
|
US7977351B2
(en)
|
2006-03-22 |
2011-07-12 |
Allergan, Inc. |
Heteroaryl dihydroindolones as kinase inhibitors
|
BRPI0711358A2
(pt)
|
2006-05-09 |
2011-09-27 |
Pfizer Prod Inc |
derivados do ácido cicloalquilamino e suas composições farmacêuticas
|
CN101443009A
(zh)
|
2006-05-18 |
2009-05-27 |
卫材R&D管理有限公司 |
针对甲状腺癌的抗肿瘤剂
|
CN101100466B
(zh)
|
2006-07-05 |
2013-12-25 |
天津和美生物技术有限公司 |
不可逆蛋白质酪氨酸磷酰化酶抑制剂及其制备和应用
|
US8246966B2
(en)
|
2006-08-07 |
2012-08-21 |
University Of Georgia Research Foundation, Inc. |
Trypanosome microsome system and uses thereof
|
WO2008026748A1
(fr)
|
2006-08-28 |
2008-03-06 |
Eisai R & D Management Co., Ltd. |
Agent antitumoral pour cancer gastrique non différencié
|
CA2663436A1
(en)
*
|
2006-10-04 |
2008-04-10 |
Pfizer Products Inc. |
Pyrido[4,3-d]pyrimidin-4(3h)-one derivatives as calcium receptor antagonists
|
EP1921070A1
(de)
|
2006-11-10 |
2008-05-14 |
Boehringer Ingelheim Pharma GmbH & Co. KG |
Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstelllung
|
US8558002B2
(en)
|
2006-11-16 |
2013-10-15 |
Allergan, Inc. |
Sulfoximines as kinase inhibitors
|
EP2099757B1
(en)
|
2006-11-16 |
2014-06-25 |
Allergan, Inc. |
Sulfoximines as kinase inhibitors
|
US8338433B2
(en)
|
2006-11-22 |
2012-12-25 |
University Of Georgia Research Foundation, Inc. |
Tyrosine kinase inhibitors as anti-kinetoplastid agents
|
WO2008083491A1
(en)
|
2007-01-11 |
2008-07-17 |
Critical Outcome Technologies Inc. |
Compounds and method for treatment of cancer
|
AU2008211952B2
(en)
|
2007-01-29 |
2012-07-19 |
Eisai R & D Management Co., Ltd. |
Composition for treatment of undifferentiated-type of gastric cancer
|
DK2118074T3
(en)
|
2007-02-01 |
2014-03-10 |
Resverlogix Corp |
Compounds for the prevention and treatment of cardiovascular diseases
|
AU2008212999A1
(en)
|
2007-02-06 |
2008-08-14 |
Boehringer Ingelheim International Gmbh |
Bicyclic heterocycles, drugs containing said compounds, use thereof, and method for production thereof
|
US20080190689A1
(en)
*
|
2007-02-12 |
2008-08-14 |
Ballard Ebbin C |
Inserts for engine exhaust systems
|
US8663915B2
(en)
|
2007-04-13 |
2014-03-04 |
Agency For Science, Technology And Research |
Methods of controlling tumorigenesis and diagnosing the risk thereof
|
EP2146779B1
(en)
|
2007-04-18 |
2016-08-10 |
Pfizer Products Inc. |
Sulfonyl amide derivatives for the treatment of abnormal cell growth
|
US20100234386A1
(en)
*
|
2007-05-10 |
2010-09-16 |
Chaudhari Amita |
Quinoxaline derivatives as pi3 kinase inhibitors
|
CA2691196C
(en)
|
2007-06-21 |
2016-05-24 |
Amgen Inc. |
Methods of synthesizing cinacalcet and salts thereof
|
WO2009057139A2
(en)
|
2007-10-29 |
2009-05-07 |
Natco Pharma Limited |
Novel 4-(tetrazol-5-yl)-quinazoline derivatives as anti cancer agents
|
EP2217240A4
(en)
|
2007-11-02 |
2012-09-12 |
Agency Science Tech & Res |
METHOD AND COMPOUNDS FOR PREVENTING AND TREATING A TUMOR
|
EP2218712B1
(en)
|
2007-11-09 |
2015-07-01 |
Eisai R&D Management Co., Ltd. |
Combination of anti-angiogenic substance and anti-tumor platinum complex
|
US8466151B2
(en)
*
|
2007-12-26 |
2013-06-18 |
Critical Outcome Technologies, Inc. |
Compounds and method for treatment of cancer
|
US8193182B2
(en)
|
2008-01-04 |
2012-06-05 |
Intellikine, Inc. |
Substituted isoquinolin-1(2H)-ones, and methods of use thereof
|
CN101965336B
(zh)
|
2008-01-04 |
2015-06-17 |
英特利凯恩有限责任公司 |
某些化学实体、组合物和方法
|
CA2711582A1
(en)
|
2008-02-07 |
2009-08-13 |
Boehringer Ingelheim International Gmbh |
Spirocyclic heterocycles, formulations containing said compounds, use thereof and processes for the preparation thereof
|
JP5739802B2
(ja)
|
2008-05-13 |
2015-06-24 |
アストラゼネカ アクチボラグ |
4−(3−クロロ−2−フルオロアニリノ)−7−メトキシ−6−{[1−(n−メチルカルバモイルメチル)ピペリジン−4−イル]オキシ}キナゾリンのフマル酸塩
|
CA2726588C
(en)
|
2008-06-03 |
2019-04-16 |
Karl Kossen |
Compounds and methods for treating inflammatory and fibrotic disorders
|
JP5602728B2
(ja)
|
2008-06-26 |
2014-10-08 |
レスバーロジックス コーポレイション |
キナゾリノン誘導体の製造方法
|
EP3023426A1
(en)
|
2008-07-17 |
2016-05-25 |
Critical Outcome Technologies, Inc. |
Thiosemicarbazone inhibitor compounds and cancer treatment methods
|
JP5539351B2
(ja)
|
2008-08-08 |
2014-07-02 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
シクロヘキシルオキシ置換ヘテロ環、これらの化合物を含有する医薬、およびそれらを生成するための方法
|
JP5764064B2
(ja)
|
2008-09-26 |
2015-08-12 |
メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. |
抗糖尿病薬として有用な新規な環状ベンゾイミダゾール誘導体
|
CN102264228A
(zh)
|
2008-10-22 |
2011-11-30 |
默沙东公司 |
用于抗糖尿病药的新的环状苯并咪唑衍生物
|
MX2011004505A
(es)
|
2008-10-29 |
2011-05-31 |
Merck Sharp & Dohme |
Derivados novedosos de bencimidazol ciclico, utiles como agentes antidiabeticos.
|
JP5557845B2
(ja)
|
2008-10-31 |
2014-07-23 |
メルク・シャープ・アンド・ドーム・コーポレーション |
糖尿病用剤として有用な新規環状ベンゾイミダゾール誘導体
|
US8710104B2
(en)
|
2008-11-07 |
2014-04-29 |
Triact Therapeutics, Inc. |
Catecholic butanes and use thereof for cancer therapy
|
US8952021B2
(en)
|
2009-01-08 |
2015-02-10 |
Resverlogix Corp. |
Compounds for the prevention and treatment of cardiovascular disease
|
US20120189641A1
(en)
|
2009-02-25 |
2012-07-26 |
OSI Pharmaceuticals, LLC |
Combination anti-cancer therapy
|
US20110171124A1
(en)
|
2009-02-26 |
2011-07-14 |
Osi Pharmaceuticals, Inc. |
In situ methods for monitoring the EMT status of tumor cells in vivo
|
EP2401613A2
(en)
|
2009-02-27 |
2012-01-04 |
OSI Pharmaceuticals, LLC |
Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
|
US8642834B2
(en)
|
2009-02-27 |
2014-02-04 |
OSI Pharmaceuticals, LLC |
Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
|
WO2010099138A2
(en)
|
2009-02-27 |
2010-09-02 |
Osi Pharmaceuticals, Inc. |
Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
|
KR101709492B1
(ko)
|
2009-03-18 |
2017-02-23 |
리스버로직스 코퍼레이션 |
신규한 소염제
|
JP2012520893A
(ja)
|
2009-03-18 |
2012-09-10 |
オーエスアイ・ファーマシューティカルズ,エルエルシー |
Egfr阻害薬及びigf−1r阻害剤の投与を含む組み合わせ癌治療
|
SI2421533T1
(sl)
|
2009-04-22 |
2019-01-31 |
Resverlogix Corp. |
Nova protivnetna sredstva
|
MX2011013016A
(es)
|
2009-06-05 |
2012-04-20 |
Link Medicine Corp |
Derivados de aminopirrolidinona y usos de los mismos.
|
US20120157471A1
(en)
|
2009-09-01 |
2012-06-21 |
Pfizer Inc. |
Benzimidazole derivatives
|
US9340555B2
(en)
|
2009-09-03 |
2016-05-17 |
Allergan, Inc. |
Compounds as tyrosine kinase modulators
|
NZ598781A
(en)
|
2009-09-03 |
2014-05-30 |
Allergan Inc |
Compounds as tyrosine kinase modulators
|
WO2011058164A1
(en)
|
2009-11-13 |
2011-05-19 |
Pangaea Biotech, S.A. |
Molecular biomarkers for predicting response to tyrosine kinase inhibitors in lung cancer
|
US8895596B2
(en)
|
2010-02-25 |
2014-11-25 |
Merck Sharp & Dohme Corp |
Cyclic benzimidazole derivatives useful as anti-diabetic agents
|
CA2794952C
(en)
|
2010-04-01 |
2018-05-15 |
Critical Outcome Technologies Inc. |
Compounds and method for treatment of hiv
|
WO2011153049A1
(en)
|
2010-06-02 |
2011-12-08 |
The Trustees Of The University Of Pennsylvania |
Methods and use of compounds that bind to her2/neu receptor complex
|
US9265739B2
(en)
|
2010-06-02 |
2016-02-23 |
The Trustees Of The University Of Pennsylvania |
Methods and use of compounds that bind to HER2/neu receptor complex
|
US9376664B2
(en)
|
2010-06-14 |
2016-06-28 |
The Scripps Research Institute |
Reprogramming of cells to a new fate
|
ES2573515T3
(es)
|
2010-06-25 |
2016-06-08 |
Eisai R&D Management Co., Ltd. |
Agente antitumoral que emplea compuestos con efecto inhibitorio de cinasas combinados
|
EA022046B1
(ru)
|
2010-07-14 |
2015-10-30 |
Новартис Аг |
Гетероциклические соединения, агонисты рецептора ip
|
ES2543151T3
(es)
|
2010-10-20 |
2015-08-17 |
Pfizer Inc |
Derivados de 2-piridina como moduladores del receptor Smoothened
|
EP2468883A1
(en)
|
2010-12-22 |
2012-06-27 |
Pangaea Biotech S.L. |
Molecular biomarkers for predicting response to tyrosine kinase inhibitors in lung cancer
|
DK2663309T3
(en)
|
2011-01-10 |
2017-06-19 |
Infinity Pharmaceuticals Inc |
METHODS FOR PRODUCING ISOQUINOLINONES AND SOLID FORMS OF ISOQUINOLINONES
|
US9134297B2
(en)
|
2011-01-11 |
2015-09-15 |
Icahn School Of Medicine At Mount Sinai |
Method and compositions for treating cancer and related methods
|
EP2492688A1
(en)
|
2011-02-23 |
2012-08-29 |
Pangaea Biotech, S.A. |
Molecular biomarkers for predicting response to antitumor treatment in lung cancer
|
WO2012129145A1
(en)
|
2011-03-18 |
2012-09-27 |
OSI Pharmaceuticals, LLC |
Nscle combination therapy
|
US8962650B2
(en)
|
2011-04-18 |
2015-02-24 |
Eisai R&D Management Co., Ltd. |
Therapeutic agent for tumor
|
WO2012149014A1
(en)
|
2011-04-25 |
2012-11-01 |
OSI Pharmaceuticals, LLC |
Use of emt gene signatures in cancer drug discovery, diagnostics, and treatment
|
JP6038128B2
(ja)
|
2011-06-03 |
2016-12-07 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
レンバチニブ化合物に対する甲状腺癌対象及び腎臓癌対象の反応性を予測及び評価するためのバイオマーカー
|
CN103619793B
(zh)
*
|
2011-06-30 |
2016-04-06 |
陶氏环球技术有限公司 |
双酚醚化合物
|
EP2751285B2
(en)
|
2011-08-31 |
2020-04-01 |
Genentech, Inc. |
Method for sensitivity testing of a tumour for a egfr kinase inhibitor
|
MD20140023A2
(ro)
|
2011-09-22 |
2014-06-30 |
Pfizer Inc. |
Derivaţi de pirolpirimidină şi purină
|
KR20140066783A
(ko)
|
2011-09-30 |
2014-06-02 |
제넨테크, 인크. |
종양 또는 종양 세포에서의 상피 또는 중간엽 표현형 및 egfr 키나제 억제제에 대한 반응의 진단 메틸화 마커
|
JP5992049B2
(ja)
|
2011-11-01 |
2016-09-14 |
レスバーロジックス コーポレイション |
置換されたキナゾリノンのための経口速放性製剤
|
US8937069B2
(en)
|
2012-01-13 |
2015-01-20 |
Novartis Ag |
Substituted pyrrolo[2,3-B]pyrazine compounds and their use
|
WO2013152252A1
(en)
|
2012-04-06 |
2013-10-10 |
OSI Pharmaceuticals, LLC |
Combination anti-cancer therapy
|
US8940742B2
(en)
|
2012-04-10 |
2015-01-27 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
WO2013190089A1
(en)
|
2012-06-21 |
2013-12-27 |
Pangaea Biotech, S.L. |
Molecular biomarkers for predicting outcome in lung cancer
|
US8828998B2
(en)
|
2012-06-25 |
2014-09-09 |
Infinity Pharmaceuticals, Inc. |
Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors
|
US9637523B2
(en)
|
2012-08-31 |
2017-05-02 |
Westfaelische Wilhelms-Universitaet Muenster |
Methods and peptides for preventing and treating a BCR-ABL and a C-ABL associated disease
|
AR092742A1
(es)
|
2012-10-02 |
2015-04-29 |
Intermune Inc |
Piridinonas antifibroticas
|
WO2014062655A1
(en)
|
2012-10-16 |
2014-04-24 |
Janssen Pharmaceutica Nv |
HETEROARYL LINKED QUINOLINYL MODULATORS OF RORyt
|
KR20150070350A
(ko)
|
2012-10-16 |
2015-06-24 |
얀센 파마슈티카 엔.브이. |
Ror-감마-t의 페닐 결합 퀴놀리닐 조절제
|
AU2013331496B2
(en)
|
2012-10-16 |
2017-07-27 |
Janssen Pharmaceutica Nv |
Methylene linked quinolinyl modulators of ROR-gamma-t
|
US9073878B2
(en)
|
2012-11-21 |
2015-07-07 |
Zenith Epigenetics Corp. |
Cyclic amines as bromodomain inhibitors
|
WO2014080291A2
(en)
|
2012-11-21 |
2014-05-30 |
Rvx Therapeutics Inc. |
Biaryl derivatives as bromodomain inhibitors
|
KR20150098605A
(ko)
|
2012-12-21 |
2015-08-28 |
에자이 알앤드디 매니지먼트 가부시키가이샤 |
퀴놀린 유도체의 비정질 형태 및 그의 제조방법
|
US9271978B2
(en)
|
2012-12-21 |
2016-03-01 |
Zenith Epigenetics Corp. |
Heterocyclic compounds as bromodomain inhibitors
|
CN105189500A
(zh)
|
2013-02-13 |
2015-12-23 |
诺华股份有限公司 |
Ip受体激动剂杂环化合物
|
AU2014223548A1
(en)
|
2013-02-26 |
2015-10-15 |
Triact Therapeutics, Inc. |
Cancer therapy
|
US9468681B2
(en)
|
2013-03-01 |
2016-10-18 |
California Institute Of Technology |
Targeted nanoparticles
|
EP2976085A1
(en)
|
2013-03-21 |
2016-01-27 |
INSERM - Institut National de la Santé et de la Recherche Médicale |
Method and pharmaceutical composition for use in the treatment of chronic liver diseases associated with a low hepcidin expression
|
CN105264380B
(zh)
|
2013-05-14 |
2017-09-05 |
卫材R&D管理有限公司 |
用于预测和评价子宫内膜癌受试者对乐伐替尼化合物响应性的生物标志
|
CA2923667A1
(en)
|
2013-09-09 |
2015-03-12 |
Triact Therapeutics, Inc. |
Cancer therapy
|
RS60093B1
(sr)
|
2013-09-16 |
2020-05-29 |
Astrazeneca Ab |
Terapeutske polimerne nanočestice i postupci njihove pripreme i primene
|
NZ718430A
(en)
|
2013-10-04 |
2021-12-24 |
Infinity Pharmaceuticals Inc |
Heterocyclic compounds and uses thereof
|
WO2015051241A1
(en)
|
2013-10-04 |
2015-04-09 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
US9221804B2
(en)
|
2013-10-15 |
2015-12-29 |
Janssen Pharmaceutica Nv |
Secondary alcohol quinolinyl modulators of RORγt
|
WO2015057626A1
(en)
|
2013-10-15 |
2015-04-23 |
Janssen Pharmaceutica Nv |
QUINOLINYL MODULATORS OF RORyT
|
US9284308B2
(en)
|
2013-10-15 |
2016-03-15 |
Janssen Pharmaceutica Nv |
Methylene linked quinolinyl modulators of RORγt
|
US10555941B2
(en)
|
2013-10-15 |
2020-02-11 |
Janssen Pharmaceutica Nv |
Alkyl linked quinolinyl modulators of RORγt
|
US9403816B2
(en)
|
2013-10-15 |
2016-08-02 |
Janssen Pharmaceutica Nv |
Phenyl linked quinolinyl modulators of RORγt
|
US9328095B2
(en)
|
2013-10-15 |
2016-05-03 |
Janssen Pharmaceutica Nv |
Heteroaryl linked quinolinyl modulators of RORgammat
|
BR112016008215A2
(pt)
|
2013-10-15 |
2017-09-26 |
Janssen Pharmaceutica Nv |
moduladores de quinolinila ligados por alquila de roryt
|
UA115388C2
(uk)
|
2013-11-21 |
2017-10-25 |
Пфайзер Інк. |
2,6-заміщені пуринові похідні та їх застосування в лікуванні проліферативних захворювань
|
EA201691872A1
(ru)
|
2014-03-19 |
2017-04-28 |
Инфинити Фармасьютикалз, Инк. |
Гетероциклические соединения для применения в лечении pi3k-гамма-опосредованных расстройств
|
CN110452216B
(zh)
|
2014-04-02 |
2022-08-26 |
英特穆恩公司 |
抗纤维化吡啶酮类
|
WO2015155624A1
(en)
|
2014-04-10 |
2015-10-15 |
Pfizer Inc. |
Dihydropyrrolopyrimidine derivatives
|
US20170027940A1
(en)
|
2014-04-10 |
2017-02-02 |
Stichting Het Nederlands Kanker Instituut |
Method for treating cancer
|
WO2015160975A2
(en)
|
2014-04-16 |
2015-10-22 |
Infinity Pharmaceuticals, Inc. |
Combination therapies
|
EA033919B1
(ru)
|
2014-04-30 |
2019-12-10 |
Пфайзер Инк. |
Соединённые циклоалкилом дигетероциклические производные
|
WO2016001789A1
(en)
|
2014-06-30 |
2016-01-07 |
Pfizer Inc. |
Pyrimidine derivatives as pi3k inhibitors for use in the treatment of cancer
|
HRP20221047T1
(hr)
|
2014-08-28 |
2022-11-11 |
Eisai R&D Management Co., Ltd. |
Derivat kinolina visoke čistoće i postupak za njegovu proizvodnju
|
US9708348B2
(en)
|
2014-10-03 |
2017-07-18 |
Infinity Pharmaceuticals, Inc. |
Trisubstituted bicyclic heterocyclic compounds with kinase activities and uses thereof
|
US10450266B2
(en)
|
2014-11-07 |
2019-10-22 |
San-Apro Limited |
Sulfonate compound, photoacid generator, and resin composition for photolithography
|
CN107223163A
(zh)
|
2014-12-24 |
2017-09-29 |
豪夫迈·罗氏有限公司 |
用于膀胱癌症的治疗,诊断和预后方法
|
JP2018505207A
(ja)
|
2015-02-11 |
2018-02-22 |
バジリア・ファルマスーチカ・インターナショナル・アーゲーBasilea Pharmaceutica International Ag |
置換モノおよびポリアザナフタレン誘導体およびその使用
|
JP6792546B2
(ja)
|
2015-02-25 |
2020-11-25 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
キノリン誘導体の苦味抑制方法
|
CA2978226A1
(en)
|
2015-03-04 |
2016-09-09 |
Merck Sharpe & Dohme Corp. |
Combination of a pd-1 antagonist and a vegfr/fgfr/ret tyrosine kinase inhibitor for treating cancer
|
CN107530356A
(zh)
|
2015-03-13 |
2018-01-02 |
雷斯韦洛吉克斯公司 |
用于治疗补体相关疾病之组合物及治疗方法
|
CN107801379B
(zh)
|
2015-06-16 |
2021-05-25 |
卫材R&D管理有限公司 |
抗癌剂
|
US10287401B2
(en)
|
2015-07-01 |
2019-05-14 |
California Institute Of Technology |
Cationic mucic acid polymer-based delivery systems
|
WO2017009751A1
(en)
|
2015-07-15 |
2017-01-19 |
Pfizer Inc. |
Pyrimidine derivatives
|
CN114230571A
(zh)
|
2015-09-14 |
2022-03-25 |
无限药品股份有限公司 |
异喹啉酮的固体形式、其制备方法、包含其的组合物及其使用方法
|
US10646465B2
(en)
|
2015-12-17 |
2020-05-12 |
Biokine Therapeutics Ltd. |
Small molecules against cancer
|
WO2017103932A1
(en)
|
2015-12-17 |
2017-06-22 |
Biokine Therapeutics Ltd. |
Small molecules for inhibiting chemokine activity, a kinase activity and/or cancer cells growth
|
WO2017161116A1
(en)
|
2016-03-17 |
2017-09-21 |
Infinity Pharmaceuticals, Inc. |
Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as pi3k kinase inhibitors
|
WO2017214269A1
(en)
|
2016-06-08 |
2017-12-14 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
JP7054681B2
(ja)
|
2016-06-24 |
2022-04-14 |
インフィニティー ファーマシューティカルズ, インコーポレイテッド |
組合せ療法
|
EP3484528B1
(en)
|
2016-07-18 |
2020-11-25 |
Janssen Pharmaceutica NV |
Tau pet imaging ligands
|
BR112019012976A2
(pt)
|
2016-12-22 |
2019-12-31 |
Amgen Inc |
inibidores de kras g12c e métodos de uso dos mesmos
|
JOP20190272A1
(ar)
|
2017-05-22 |
2019-11-21 |
Amgen Inc |
مثبطات kras g12c وطرق لاستخدامها
|
IL293443A
(en)
|
2017-09-08 |
2022-07-01 |
Amgen Inc |
kras g12c inhibitors and methods of using them
|
CA3099118A1
(en)
|
2018-05-04 |
2019-11-07 |
Amgen Inc. |
Kras g12c inhibitors and methods of using the same
|
WO2019213516A1
(en)
|
2018-05-04 |
2019-11-07 |
Amgen Inc. |
Kras g12c inhibitors and methods of using the same
|
CA3099045A1
(en)
|
2018-05-10 |
2019-11-14 |
Amgen Inc. |
Kras g12c inhibitors for the treatment of cancer
|
US11096939B2
(en)
|
2018-06-01 |
2021-08-24 |
Amgen Inc. |
KRAS G12C inhibitors and methods of using the same
|
AU2019284472A1
(en)
|
2018-06-11 |
2020-11-26 |
Amgen Inc. |
KRAS G12C inhibitors for treating cancer
|
WO2020050890A2
(en)
|
2018-06-12 |
2020-03-12 |
Amgen Inc. |
Kras g12c inhibitors and methods of using the same
|
CN113194954A
(zh)
|
2018-10-04 |
2021-07-30 |
国家医疗保健研究所 |
用于治疗角皮病的egfr抑制剂
|
JP2020090482A
(ja)
|
2018-11-16 |
2020-06-11 |
アムジエン・インコーポレーテツド |
Kras g12c阻害剤化合物の重要な中間体の改良合成法
|
WO2020106640A1
(en)
|
2018-11-19 |
2020-05-28 |
Amgen Inc. |
Kras g12c inhibitors and methods of using the same
|
JP7377679B2
(ja)
|
2018-11-19 |
2023-11-10 |
アムジエン・インコーポレーテツド |
がん治療のためのkrasg12c阻害剤及び1種以上の薬学的に活性な追加の薬剤を含む併用療法
|
US20220002311A1
(en)
|
2018-12-20 |
2022-01-06 |
Amgen Inc. |
Kif18a inhibitors
|
MX2021007158A
(es)
|
2018-12-20 |
2021-08-16 |
Amgen Inc |
Heteroarilamidas utiles como inhibidores de kif18a.
|
WO2020132651A1
(en)
|
2018-12-20 |
2020-06-25 |
Amgen Inc. |
Kif18a inhibitors
|
TW202034924A
(zh)
|
2018-12-20 |
2020-10-01 |
美商安進公司 |
Kif18a 抑制劑
|
CN109776413A
(zh)
*
|
2019-01-29 |
2019-05-21 |
天津科技大学 |
一种具有降糖活性的异喹啉衍生物和应用
|
KR20210146288A
(ko)
|
2019-03-01 |
2021-12-03 |
레볼루션 메디슨즈, 인크. |
이환식 헤테로사이클릴 화합물 및 이의 용도
|
EP3931195A1
(en)
|
2019-03-01 |
2022-01-05 |
Revolution Medicines, Inc. |
Bicyclic heteroaryl compounds and uses thereof
|
EP3738593A1
(en)
|
2019-05-14 |
2020-11-18 |
Amgen, Inc |
Dosing of kras inhibitor for treatment of cancers
|
MX2021014008A
(es)
|
2019-05-15 |
2022-02-11 |
Alonbio Ltd |
Moléculas pequeñas para tratar el cáncer, inhibir la actividad de quimiocinas y/o inducir la muerte celular.
|
JOP20210310A1
(ar)
|
2019-05-21 |
2023-01-30 |
Amgen Inc |
أشكال الحالة الصلبة
|
MX2022001295A
(es)
|
2019-08-02 |
2022-02-22 |
Amgen Inc |
Inhibidores de kif18a.
|
MX2022001302A
(es)
|
2019-08-02 |
2022-03-02 |
Amgen Inc |
Inhibidores de kif18a.
|
MX2022001181A
(es)
|
2019-08-02 |
2022-02-22 |
Amgen Inc |
Inhibidores de kif18a.
|
CN114401953A
(zh)
|
2019-08-02 |
2022-04-26 |
美国安进公司 |
Kif18a抑制剂
|
MX2022004656A
(es)
|
2019-10-24 |
2022-05-25 |
Amgen Inc |
Derivados de piridopirimidina utiles como inhibidores de kras g12c y kras g12d en el tratamiento del cancer.
|
CA3160142A1
(en)
|
2019-11-04 |
2021-05-14 |
Revolution Medicines, Inc. |
Ras inhibitors
|
US11739074B2
(en)
|
2019-11-04 |
2023-08-29 |
Revolution Medicines, Inc. |
Ras inhibitors
|
AU2020379734A1
(en)
|
2019-11-04 |
2022-05-05 |
Revolution Medicines, Inc. |
Ras inhibitors
|
AU2020380315A1
(en)
|
2019-11-08 |
2022-05-26 |
Revolution Medicines, Inc. |
Bicyclic heteroaryl compounds and uses thereof
|
CN114728960A
(zh)
|
2019-11-14 |
2022-07-08 |
美国安进公司 |
Kras g12c抑制剂化合物的改善的合成
|
AU2020383535A1
(en)
|
2019-11-14 |
2022-05-05 |
Amgen Inc. |
Improved synthesis of KRAS G12C inhibitor compound
|
CN114980976A
(zh)
|
2019-11-27 |
2022-08-30 |
锐新医药公司 |
共价ras抑制剂及其用途
|
WO2021142026A1
(en)
|
2020-01-07 |
2021-07-15 |
Revolution Medicines, Inc. |
Shp2 inhibitor dosing and methods of treating cancer
|
WO2021257736A1
(en)
|
2020-06-18 |
2021-12-23 |
Revolution Medicines, Inc. |
Methods for delaying, preventing, and treating acquired resistance to ras inhibitors
|
JP2023536634A
(ja)
|
2020-08-07 |
2023-08-28 |
アトス セラピューティクス,インコーポレイテッド |
自己免疫疾患および癌の処置のための小分子
|
CN116209438A
(zh)
|
2020-09-03 |
2023-06-02 |
锐新医药公司 |
使用sos1抑制剂治疗具有shp2突变的恶性疾病
|
CN116457358A
(zh)
|
2020-09-15 |
2023-07-18 |
锐新医药公司 |
作为ras抑制剂以治疗癌症的吲哚衍生物
|
CN112047882A
(zh)
*
|
2020-10-15 |
2020-12-08 |
天津科技大学 |
一种异喹啉和喹啉衍生物用于制备降血脂药物方面中的新应用
|
CA3203111A1
(en)
|
2020-12-22 |
2022-06-30 |
Kailiang Wang |
Sos1 inhibitors and uses thereof
|
WO2022175752A1
(en)
|
2021-02-19 |
2022-08-25 |
Sudo Biosciences Limited |
Tyk2 inhibitors and uses thereof
|
WO2022235870A1
(en)
|
2021-05-05 |
2022-11-10 |
Revolution Medicines, Inc. |
Ras inhibitors for the treatment of cancer
|
EP4334324A1
(en)
|
2021-05-05 |
2024-03-13 |
Revolution Medicines, Inc. |
Covalent ras inhibitors and uses thereof
|
EP4334321A1
(en)
|
2021-05-05 |
2024-03-13 |
Revolution Medicines, Inc. |
Ras inhibitors
|
AR127308A1
(es)
|
2021-10-08 |
2024-01-10 |
Revolution Medicines Inc |
Inhibidores ras
|
WO2023114954A1
(en)
|
2021-12-17 |
2023-06-22 |
Genzyme Corporation |
Pyrazolopyrazine compounds as shp2 inhibitors
|
EP4227307A1
(en)
|
2022-02-11 |
2023-08-16 |
Genzyme Corporation |
Pyrazolopyrazine compounds as shp2 inhibitors
|
WO2023172940A1
(en)
|
2022-03-08 |
2023-09-14 |
Revolution Medicines, Inc. |
Methods for treating immune refractory lung cancer
|
WO2023240263A1
(en)
|
2022-06-10 |
2023-12-14 |
Revolution Medicines, Inc. |
Macrocyclic ras inhibitors
|